Ensayos clínicos A continuación, se enumeran los ensayos clínicos actuales.135 estudios en Neurología (solo estudios abiertos). Filtra esta lista de estudios por sede, estatus, etc. A Study to Evaluate Newly-diagnosed Idiopathic Generalized Epilepsy Rochester, Minn. The purpose of this study is to identify clinical characteristics and biomarkers predictive of disease outcome, progression, and treatment response in participants with idiopathic generalized epilepsy (IGE). Posterior Fossa Decompression with or without Duraplasty for Chiari Type I Malformation with Syringomyelia Rochester, Minn. The purpose of this study is to determine whether a posterior fossa decompression or a posterior fossa decompression with duraplasty results in better patient outcomes with fewer complications and improved quality of life in those who have Chiari malformation type I and syringomyelia. A Study of Mood Symptoms in Epilepsy Patients Rochester, Minn. The purpose of this study is to track neuropsychiatric symptoms in patients with epilepsy. Natural History Study Protocol in PMM2-CDG (CDG-Ia) Rochester, Minn. Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG) This is a natural history (observational) protocol designed to collect clinical and biological information in patients with PMM2-CDG (CDG-Ia). Data from this natural history study will be used to determine a set of clinical and biological parameters that will be used for primary and secondary endpoints in a later clinical trial with a new chemical entity, Lipo-M1P. Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma Rochester, Minn. This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT)/Wingless (WNT)-driven medulloblastoma. Recent studies using chemotherapy and radiation therapy have been shown to be effective in treating patients with WNT-driven medulloblastoma. However, there is a concern about the late side effects of treatment, such as learning difficulties, lower amounts of hormones, or other problems in performing daily activities. Radiotherapy uses high-energy radiation from x-rays to kill cancer cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, vincristine sulfate, cyclophosphamide and lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving reduced craniospinal radiation therapy and chemotherapy may kill tumor cells and may also reduce the late side effects of treatment. HEALEY ALS Platform Trial Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the safety and effectiveness of investigational products for the treatment of ALS. A Study to Evaluate Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Patients Rochester, Minn. The purpose of this study is to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims: The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech Rochester, Minn. The purpose of this study is to identify and distinguish two different types of Progressive Apraxia of Speech through clinical imaging and testing. A Study to Investigate the Safety and Tolerability of Single and Multiple Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents with Dravet Syndrome Rochester, Minn. The purpose of this study is to evaluate the safety and tolerability of single-ascending doses of STK-001 in patients with Dravet Syndrome. A Study of Pyridostigmine in Postural Tachycardia Syndrome Rochester, Minn. This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure. Numeración de páginas Estudios clínicos Ir a página 11 Ir a página 22 Ir a página 33 Ir a página 44 Ir a página 55 SiguientePróxima página Solicite una consulta Centros, viajes y alojamientoInvestigación April 01, 2023 Comparte en: FacebookTwitter Mayo Clinic de Rochester, Minnesota, Mayo Clinic de Phoenix y Scottsdale, Arizona, y Mayo Clinic de Jacksonville, Florida, han sido reconocidas entre los mejores hospitales para neurología y neurocirugía del país durante el período 2022-2023 por U.S. News & World Report. Obtén más información sobre este gran honor NeurologíaPágina inicialdel departamentoSeccionesSolicita una consultaDescripción generalAnálisis y procedimientosEnfermedades tratadasMédicosGrupos especializadosConocimientos y categoríasCentros, viajes y alojamientoEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos y seguroNoticias de Mayo ClinicRemisiones Investigación: todo es por los pacientes Mostrar la transcripción Para video Investigación: todo es por los pacientes [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. SeccionesSolicita una consultaDescripción generalAnálisis y procedimientosEnfermedades tratadasMédicosGrupos especializadosConocimientos y categoríasCentros, viajes y alojamientoEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos y seguroNoticias de Mayo ClinicRemisiones ORG-20117054 Centros y departamentos médicos Neurología